Keynote Speakers
Ellen Beasley Senior Vice President, Genomic Health Inc |
Xandra Breakefield Professor, Mass General Hospital (MGH)/Harvard Medical School |
Maximilian Diehn Assistant Professor, Stanford University School of Medicine |
Nicholas Dracopoli Vice President/Head, Johnson & Johnson |
Raghu Kalluri Professor and Chairman, Department of Cancer Biology, University of Texas MD Anderson Cancer Center |
Shana Kelley Professor, University of Toronto |
Walter Koch Vice President, Roche Molecular Systems |
Minetta Liu Associate Professor and Chair, Oncology Research, Mayo Clinic |
Ranjan Perera Associate Professor, Scientific Director Genomics and Bioinformatics, Sanford Burnham Medical Research Institute |
Oscar Puig Biomarker Leader, Hoffmann La Roche |
Chamindie Punyadeera Associate Professor, Institute of Health and Biomedical Innovation, Queensland University of Technology |
Dominique PV de Kleijn Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands |
Frank Slack Director, Institute for RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center/Harvard Medical School |
Hsian-Rong Tseng Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles |
David Wong Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles |
OverviewThe 2nd Annual Biofluid Biopsies and High Value Diagnostics 2015 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.
The Biofluid Biopsies Conference Track focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.
The High-Value Diagnostics Conference Track explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for patient monitoring and precision/targeted medicine.
We also explore the front-end sample preparation challenges and approaches for the deployment of various biofluid classes (plasma, serum, urine, cerebrospinal fluid, ovarian follicular fluid, and saliva) into diagnostics development in both the conference tracks.
All conference delegates receive access to both concurrent, co-located conference tracks enabling maximal learning and maximizing networking opportunities.
Present Your Research at this Conference in a Poster to a Worldwide Audience. Poster Submission Deadline: November 2, 2015
Agenda Topics- Circulating Tumor Cells (CTCs): Potential for Development of Biofluid-based Biopsies
- Circulating Tumor DNA (ctDNA): Potential for Development of Biofluid-based Biopsies
- Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNA -- Value for Developing Biofluid Biopsies
- Extracellular Vesicles (EVs): Potential for Development of Biofluid-based Biopsies
- Potential of microRNAs from Biofluids as Biomarkers for Diagnostics Development and as Companion Diagnostics
- Preparation of Clinical Samples for Biofluid-based Biopsies
- US vs. EU vs. Asia/Pacific Regulatory Landscape for Novel High-Value Diagnostics
Sponsorship and Exhibition OpportunitiesJeff Fan, Exhibition Manager jeff@selectbioconferences.com +1-510-857-4865
|
Distinguished FacultyTony Godfrey, Associate Chair – Research, Department of Surgery, Boston University Medical Center Chris Karlovich, Associate Director, Molecular Diagnostics, Clovis Oncology, Inc. Shannon Pendergrast, Chief Scientific Officer, Ymir Genomics Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D Anton Wellstein, Professor, Georgetown University Medical Center Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University Alexander Sasha Vlassov, Senior Manager R&D , Thermo Fisher Scientific Robert Kinders, Sr. Principal Scientist and Head, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research
|
Corporate Sponsors | Web Sponsors | Offical Journal Partner | Networking |
| | | |
|